China Anti-Bribery Rules Raise Questions For Life Sciences

Law360, New York (February 27, 2014, 6:40 PM EST) -- China’s recent crackdown on bribery and corruption has been widely publicized, with enforcement particularly intense in the health care industry. In parallel with the heightened enforcement activity throughout China, the nation’s health care regulator, the National Health and Family Planning Commission,[1] recently launched a three-year anti-commercial bribery campaign intended to specifically target 10 large cities and provinces, including Beijing, Shanghai, Tianjin, Zhejiang, Guangdong and Sichuan.

The first significant policy outgrowth of this anti-bribery campaign came in the final days of December 2013, when the commission issued...
To view the full article, register now.